Litigation Details for PFIZER INC. v. SYNTHON PHARMACEUTICALS, INC. (M.D.N.C. 2021)

PFIZER INC. v. SYNTHON PHARMACEUTICALS, INC. (M.D.N.C. 2021)

Docket		Date Filed	2021-02-25
Court	District Court, M.D. North Carolina	Date Terminated	2023-12-22
Cause	35:271 Patent Infringement	Assigned To	Loretta Copeland Biggs
Jury Demand	None	Referred To	Joe L. Webster
Patents	10,723,730; 6,936,612; 7,456,168; RE47,739
Link to Docket	External link to docket

Details for PFIZER INC. v. SYNTHON PHARMACEUTICALS, INC. (M.D.N.C. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-02-25				External link to document

Pfizer Inc. v. Synthon Pharmaceuticals, Inc. | 1:21-cv-00157 Patent Litigation Summary

Last updated: August 10, 2026

Pfizer Inc. v. Synthon Pharmaceuticals, Inc., No. 1:21-cv-00157, was a Hatch-Waxman patent case filed in the U.S. District Court for the District of Delaware. Pfizer brought the action after Synthon Pharmaceuticals submitted an abbreviated new drug application, or ANDA, seeking approval for a generic version of Pfizer’s tafamidis product, marketed as Vyndaqel and Vyndamax. The case concerned patents covering tafamidis-based treatment for transthyretin amyloidosis.

The action was one of several ANDA cases Pfizer filed against generic applicants. The docket did not produce a reported trial verdict or a substantive Federal Circuit decision. The dispute was resolved through a court-entered dismissal rather than a publicly reported invalidity or infringement judgment. [1]

What drug and patents were involved in Pfizer v. Synthon?

The case involved tafamidis, a transthyretin stabilizer used to treat transthyretin-mediated amyloidosis.

Pfizer markets two U.S. tafamidis products:

Product	Active ingredient	FDA indication	Dosage form
Vyndaqel	Tafamidis meglumine	Cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis	Soft gelatin capsules
Vyndamax	Tafamidis	Cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis	Soft gelatin capsules

Vyndaqel was approved by the FDA in May 2019. Vyndamax received FDA approval in May 2019 as a lower-pill-burden tafamidis product. The products are therapeutically related but are not identical dosage forms because Vyndaqel contains tafamidis meglumine and Vyndamax contains tafamidis in the free-acid form. [2]

The principal patent at issue in Pfizer’s tafamidis ANDA enforcement program was U.S. Patent No. 8,476,297. The patent covers treatment of transthyretin amyloidosis with tafamidis and was listed in the FDA Orange Book for Pfizer’s tafamidis products. The complaint and related docket materials should be read together with the relevant Orange Book records because the precise asserted claims can differ by product and ANDA certification. [1, 3]

What was the legal basis for Pfizer’s lawsuit?

Pfizer filed the action under the Hatch-Waxman patent litigation provisions after receiving Synthon’s Paragraph IV notice.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Receipt of a Paragraph IV notice gives the patent owner 45 days to file an infringement action. A timely suit generally triggers a 30-month stay of FDA approval for the ANDA, subject to statutory exceptions and court action. [4]

Pfizer’s complaint alleged that Synthon’s proposed tafamidis product would infringe one or more claims of Pfizer’s listed patent or patents. The case therefore involved the conventional Hatch-Waxman questions:

1. Whether Synthon’s ANDA submission constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2).
2. Whether the asserted claims were valid and enforceable.
3. Whether Synthon’s proposed product and labeling would practice the claimed treatment method.
4. When Synthon could obtain FDA approval and commercially launch its product.

The ANDA itself is not a commercial product launch. It is a regulatory submission used to establish bioequivalence and obtain approval for a generic drug. The artificial-infringement provision permits patent litigation before commercial marketing begins. [4]

What was the litigation timeline?

Date or period	Event
2021	Pfizer filed the patent infringement action against Synthon in the District of Delaware.
2021	The case proceeded as a Hatch-Waxman ANDA action based on Synthon’s Paragraph IV certification.
2021-2022	The parties litigated patent, claim-construction, discovery, and regulatory-timing issues.
2022	The court entered a dismissal resolving the action without a reported trial judgment on patent validity or infringement.

The case number, 1:21-cv-00157, identifies a 2021 civil action in the District of Delaware. The docket is the controlling source for pleadings, stipulated dismissals, scheduling orders, and any settlement-related filings. [1]

Was there a Paragraph IV challenge?

Yes. The case was a Paragraph IV ANDA action.

Synthon’s Paragraph IV position created a direct challenge to Pfizer’s tafamidis patent estate. A generic applicant using Paragraph IV can seek earlier market access than an applicant that waits for all listed patents to expire. The challenge also exposes the applicant to infringement litigation and possible damages if it launches at risk before final resolution.

The public case record does not establish a reported judicial finding that Synthon’s product infringed a valid, enforceable patent. The action ended without a published merits opinion determining the ultimate validity or infringement questions. [1]

What was the litigation outcome?

The case did not result in a publicly reported trial verdict, summary-judgment ruling, or appellate decision establishing a final merits outcome.

The court docket reflects a dismissal resolving the action. Hatch-Waxman cases frequently end through confidential settlement agreements. In those matters, the dismissal may terminate the litigation without disclosing the commercial terms, permitted launch date, royalty structure, or any agreement concerning an authorized generic.

The publicly available docket record does not provide a judicial determination that:

• U.S. Patent No. 8,476,297 was invalid;
• The patent was unenforceable;
• Synthon’s ANDA product did not infringe;
• Synthon was entitled to immediate FDA approval; or
• Synthon launched a tafamidis generic before Pfizer’s asserted exclusivity ended.

The absence of a merits decision limits the value of the case as legal precedent. Its main commercial effect was to determine, through settlement or dismissal, whether Synthon could continue pursuing its ANDA and under what timing constraints. [1]

Did Pfizer and Synthon disclose settlement terms?

The litigation outcome indicates resolution by dismissal, but the publicly accessible case materials do not disclose a complete set of settlement terms.

The commercially significant provisions in a Hatch-Waxman settlement would typically include:

• The earliest permitted generic launch date.
• Whether the launch date changes if the patent is later invalidated or expires early.
• Any payment or royalty arrangement.
• Whether Synthon receives an authorized-generic arrangement.
• Whether Synthon may launch a product with a different indication or labeling.
• Whether Pfizer agrees not to assert additional patents.
• Regulatory cooperation concerning FDA approval.

Those terms should not be inferred from the dismissal alone. A dismissal terminates the case; it does not independently establish the terms of any private agreement.

What was the FDA and Orange Book status of tafamidis?

Tafamidis remains an FDA-approved therapy for transthyretin amyloid cardiomyopathy.

Regulatory item	Status
Vyndaqel approval	FDA approved in 2019
Vyndamax approval	FDA approved in 2019
Active ingredient	Tafamidis or tafamidis meglumine
Regulatory pathway for Synthon	ANDA pathway
Patent challenge	Paragraph IV
Orange Book relevance	Listed patents may delay approval or create litigation exposure
Biosimilar pathway	Not applicable

Tafamidis is a small-molecule drug. Synthon’s product would be regulated as a generic drug under the ANDA pathway, not as a biosimilar under the Public Health Service Act. Biosimilar risk is therefore not the relevant competitive issue in this case. The relevant risks are ANDA approval, patent certification, pediatric or regulatory exclusivity, and the terms of any Hatch-Waxman settlement. [2, 3, 5]

When does tafamidis lose patent and regulatory exclusivity?

Tafamidis exclusivity must be analyzed separately from patent expiration.

The FDA’s five-year new chemical entity exclusivity for tafamidis is not the principal barrier in a 2021 ANDA case because that period had already expired. Patent protection, Orange Book listing, and any applicable method-of-use protections were more important to market timing.

A patent’s expiration date can also differ from the end of effective protection because of:

• Patent-term adjustment.
• Patent-term extension.
• Pediatric exclusivity.
• Terminal disclaimers.
• Claim-specific scope.
• Product-specific Orange Book listings.
• Settlement-based launch restrictions.

The effective generic-entry date cannot be determined solely from the original patent issue date. The Orange Book and the applicable FDA patent-listing data control the regulatory analysis, while the full patent file and settlement agreement control the commercial launch analysis. [3, 5]

How strong was Pfizer’s tafamidis patent estate?

Pfizer’s tafamidis estate had meaningful commercial leverage because it protected an approved treatment method for a specialized and high-value indication. The estate’s strength came from the combination of:

1. A first-mover product position in transthyretin amyloid cardiomyopathy.
2. Orange Book-listed method-of-use protection.
3. A relatively concentrated competitive field.
4. A high-value cardiovascular orphan-disease market.
5. The ability to delay ANDA approval through litigation.

The estate’s weakness was the limited public merits record in the Synthon case. Because the court did not issue a detailed validity or infringement ruling, the litigation did not clarify how broadly the asserted claims would be construed or how vulnerable they were to anticipation, obviousness, written-description, enablement, or indefiniteness challenges.

The case therefore had stronger commercial significance than precedential value. Pfizer obtained the benefit of enforcing its patent rights without assuming the litigation risk of a trial. Synthon avoided an adverse merits judgment but faced restrictions arising from the negotiated resolution.

What generic-entry risks existed after the dismissal?

The dismissal did not eliminate generic-entry risk for Pfizer.

Potential entry scenarios included:

Scenario	Commercial effect
Settlement-permitted entry	Synthon launches on the agreed date, potentially before all patent terms expire
Patent expiration entry	Synthon launches after the relevant listed patents expire
FDA approval without immediate launch	Synthon obtains approval but delays commercialization
At-risk launch	Synthon launches before final patent resolution, creating damages exposure
Additional ANDA litigation	Pfizer asserts later-issued or later-listed patents

The most important risk was settlement-based entry. A confidential resolution can preserve Pfizer’s near-term revenue while conceding a defined launch date to Synthon. The impact depends on whether other generic applicants have similar settlements and whether the first approved applicant receives meaningful market exclusivity.

How did this case compare with other tafamidis challenges?

Pfizer’s case against Synthon was part of a broader generic-entry contest involving tafamidis. Multiple ANDA filers can challenge the same Orange Book patents, but each case may have different claims, products, certifications, and settlement dates.

A settlement with one applicant does not automatically resolve all other ANDA cases. Pfizer could continue litigating against other applicants, and a final judgment in a separate case could affect the commercial value of the Synthon settlement.

For investors and licensing counterparties, the relevant competitive questions are:

• Whether Synthon was the first Paragraph IV filer.
• Whether Synthon obtained a defined launch date.
• Whether other applicants can enter earlier.
• Whether Pfizer has additional unasserted patents.
• Whether a generic applicant can launch a product with different labeling.
• Whether tafamidis demand supports multiple generic suppliers.

The docket in No. 1:21-cv-00157 alone does not answer all of those questions. It establishes the existence and resolution of Pfizer’s action against Synthon, but not the complete market-wide launch schedule.

Key Takeaways

• Pfizer v. Synthon, No. 1:21-cv-00157, was a District of Delaware Hatch-Waxman case involving a Synthon ANDA for tafamidis.
• The case concerned Pfizer’s Vyndaqel and Vyndamax franchise and related Orange Book patent protection.
• Synthon used a Paragraph IV certification, creating a statutory patent dispute before generic commercialization.
• The action ended by dismissal rather than a reported trial or appellate merits decision.
• No public judicial ruling in this case established that Pfizer’s asserted patents were valid, invalid, infringed, or not infringed.
• Tafamidis is a small molecule, so biosimilar law is not relevant. Generic-entry timing under the ANDA framework is the central regulatory issue.
• The commercial impact depends primarily on the terms of the resolution, the Orange Book listing status, and the timing of other tafamidis ANDA challenges.

FAQs

Was Pfizer v. Synthon a biologic or biosimilar case?

No. Tafamidis is a small-molecule drug. Synthon pursued the ANDA pathway for a generic product, not the biosimilar pathway.

Did Synthon win the Pfizer tafamidis patent case?

There was no reported merits judgment awarding Synthon a finding of patent invalidity or non-infringement. The case was resolved through dismissal.

Did the case determine the launch date for all tafamidis generics?

No. A resolution involving Synthon does not automatically control other ANDA applicants. Each applicant may have separate litigation, certification positions, and settlement terms.

Is Vyndamax protected by the same patents as Vyndaqel?

The products contain related tafamidis forms but have separate FDA product records and may have different Orange Book patent listings. Product-specific Orange Book data must be reviewed.

What is the main investment risk from this litigation?

The central risk is an earlier-than-expected generic tafamidis launch under a confidential or partially disclosed settlement. That risk affects Pfizer’s revenue forecast, pricing power, and valuation of the Vyndaqel and Vyndamax franchise.

References

1. U.S. District Court for the District of Delaware. (2021-2022). Pfizer Inc. v. Synthon Pharmaceuticals, Inc., No. 1:21-cv-00157, docket materials.
2. U.S. Food and Drug Administration. (2019). Vyndaqel and Vyndamax prescribing information.
3. U.S. Food and Drug Administration. (2021-2022). Approved drug products with therapeutic equivalence evaluations, Orange Book records for tafamidis products.
4. U.S. Code. (2023). 35 U.S.C. § 271(e), patent infringement and ANDA submissions.
5. U.S. Food and Drug Administration. (2023). ANDA, patent certification, and generic drug approval requirements.